Capella Bioscience completes Series A financing of £11m
To progress antibody pipeline towards clinical evaluation
London, UK-based monoclonal antibody developer Capella Bioscience has closed a £11m (US$15.5m), Series A financing round.
Advent Life Sciences, Medicxi Ventures, and Osage University Partners have provided the finances.
The company said the new capital will progress its novel therapeutic antibody discovery programmes towards clinical evaluation.
'We are delighted to receive this support from a strong and knowledgeable syndicate of investors to progress our development programmes,' said Steve Holmes, COO of Capella.
'In addition to providing significant financial resources, these experienced investors bring Capella a wealth of operational, medical, and industry expertise along with key relationships that will serve the company well during this important stage of growth and development.'
In connection with the financing, Bill Harrington of Osage University Partners will join Capella's Board in an observer role.
